With improvements in axillary staging, the advent of modern chemotherapy regimens, the use of aromatase inhibitors, and the implementation of targeted therapies the absolute risk of breast cancer recurrence has significantly decreased. This evidence concerns the gene CYP19A1 and breast carcinoma.